Cabio Biotech (Wuhan) Co., Ltd. (688089.SS)

CNY 20.17

(-0.93%)

Market Cap (In CNY)

3.39 Billion

Revenue (In CNY)

443.8 Million

Net Income (In CNY)

91.37 Million

Avg. Volume

2.59 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
9.98-30.12
PE
-
EPS
-
Beta Value
0.629
ISIN
CNE100005X31
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dewei Yi
Employee Count
-
Website
https://www.cabio.cn
Ipo Date
2019-12-19
Details
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

More Stocks